SCOHIA PHARNA, Inc. / Japan
台灣醫療科技展展位:X
SCOHIA PHARMA, Inc. is a biotech venture with substantial research and development capabilities for drug discovery in the fields of cardiovascular, metabolic and renal areas. We began operations in April 2017 as a carving-out venture from Takeda Pharmaceutical Company Limited with highly talented and experienced human resources as well as multiple pre-clinical and clinical assets. We strive to deliver truly efficacious and innovative therapeutic medicine to patients around the world.
We are funded by three major Japanese companies: Innovation Network Corporation of Japan (now INCJ, Ltd.), Takeda Pharmaceutical Company Limited and MEDIPAL HOLDINGS CORPORATION.
 
成立時間2017
資本額TWD 0
員工數0
產品/服務類別
生技製藥
採購與合作需求項目
Not applicable
供應與銷售項目
Preclinical and clinical drug candidates in cardiovascular, metabolic and renal disease areas as out-licensing candidates
特色產品
Imarikiren (development code: SCO-272), a direct renin inhibitor, is expected to control blood pressure and protect kidney by inhibiting the renin-angiotensin-aldosterone system (RAAS) and manage various diseases caused by RAAS.

The Phase 2b, dose-finding study in patients with type 2 DM (diabetes mellitus) and microalbuminuria in Japan had been completed with positive results.

In addition to the oral formulation, injection type of formulation is under development with its very good solubility profile. Currently a very limited number of injectable RAAS inhibitors is on the market and imarikiren could add another option of blood pressure control for those who may need parenteral administration such as dialysis patients.
應用範疇
Worldwide
特色優勢
產品/服務類別
生技製藥
SCO-267, identified by SCOHIA researchers and collaborators, is a GPR40 full agonist, which has a new chemical structure and binds to a site independent of the fasiglifam binding site. Contrary to GPR40 partial agonists, which increase insulin secretion only, a GPR40 full agonist such as SCO-267 is unique in that it increases the production of islet hormones and gut hormones.



In a Phase 1 study, a single dose of SCO-267 stimulated islet and gut hormones and remarkably improved glucose tolerance in diabetic patients.



In preclinical studies, SCO-267 increases the levels of GLP-1, GIP, and peptide YY, and thus, decreases body weight in obesity models. In addition to these hormones, SCO-267 increases insulin secretion and improves glucose control more effectively than GPR40 partial agonists and dipeptidyl peptidase-4 inhibitors. Furthermore, SCO-267 increases the secretion of glucagon, which has a major role in liver metabolism and function, and improves liver parameters in preclinical models with liver-dysfunctions.



Based on these observations, SCO-267 may be a new drug option for the treatment of diabetes, obesity, and non-alcoholic steatohepatitis. Moreover, a Phase 2 study is in preparation.
應用範疇
Worldwide
特色優勢
產品/服務類別
生技製藥
Enteropeptidase is a serine protease, localized to the brush border of the duodenal and jejunal mucosa. SCOHIA researchers and collaborators discovered SCO-792, which is a new potent orally available enteropeptidase inhibitor, and revealed its therapeutic benefits in preclinical studies.



Our preclinical studies showed that SCO-792 is highly effective in improving metabolic disease, obesity, and liver dysfunction. In addition, SCO-792 improves kidney parameters in preclinical diabetic and non-diabetic kidney disease models.



The similarity in amino acid changes between enteropeptidase inhibition and surgical gastric bypass induces potent therapeutic effects; similar mechanisms may contribute to the therapeutic effects of SCO-792. In our Phase 2 proof of concept study in which SCO-792 and placebo were used to treat diabetic patients with obesity for 12 weeks, we found that SCO-792 led to more reduced body weight compared to placebo.



Ongoing Phase 2 proof of concept studies in patients with kidney disease show that SCO-792 might have a renal protective effect.
應用範疇
Worldwide
特色優勢
產品/服務類別
生技製藥
SCO-116, identified by SCOHIA researchers, is a novel NRF2 activator that selectively inhibits the interaction of KEAP1 with NRF2. An orally available SCO-116 selectively activates NRF2 in the liver, kidney, and gut, which likely results in good efficacy and safety profiles.



The therapeutic efficacy of SCO-116 has been demonstrated in preclinical NASH and kidney disease models; hence, this drug may be effective in clinical settings. Investigational New Drug-enabling studies are ongoing in preparation for advancement to clinical development.
應用範疇
Worldwide
特色優勢
產品/服務類別
生技製藥
SCO-094, identified by SCOHIA researchers and collaborators, is a novel dual agonist for GLP-1R and GIPR. Preclinical studies have shown that SCO-094 is more effective in improving diabetes and obesity than GLP-1R mono agonist. It is equally as or more effective than the same class

GLP-1R/GIPR dual agonists. Also, SCO-094 improved liver parameters in diabetes and obesity. Since the pharmacokinetics of SCO-094 in monkeys shows potential for the once-weekly dosing. SCOHIA is doing studies to advance the clinical development of this regimen. An oral absorbability of SCO-094 seen in early discovery works is promising to expand the route of administration. Collectively, SCO-094 may be a new drug used to improve diabetes, obesity, and non-alcoholic steatohepatitis (NASH).



Currently, SCOHIA is conducting a phase 1 trial of the once-daily dose of SCO-094 in type 2 diabetes patients in the UK.
應用範疇
Worldwide excluding APAC including Japan
特色優勢
產品/服務類別
生技製藥
最新商機情報
你可能有興趣的產品服務
你可能有興趣的機構/企業
© Institute for Biotechnology and Medicine Industry & Research Center for Biotechnology and Medicine Policy
聯絡我們
Loading...